Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 20/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.68 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116588 | 0.88 | ADRB1 (0.86) | ADRB1ADRB2 | |
| Acetic Acid SCHEMBL5122650 | 0.85 | ADRB1 (0.81) | ADRB1ADRB2 | |
| Dimethylamine SCHEMBL6051759 | 0.80 | ADRB1 (0.93) | ADRB1ADRB2 | |
| SCHEMBL5115456 | 0.79 | ADRB2 (0.67) | ADRB1ADRB2ADRB3 | |
| SCHEMBL5115447 | 0.79 | ADRB2 (0.67) | ADRB1ADRB2ADRB3 | |
| SCHEMBL4627270 | 0.78 | ADRB2 (0.64) | ADRB1ADRB2ADRB3 | |
| SCHEMBL5126828 | 0.77 | ADRB2 (0.66) | ADRB1ADRB2ADRB3 | |
| SCHEMBL5126823 | 0.77 | ADRB2 (0.66) | ADRB1ADRB2ADRB3 | |
| SCHEMBL5127611 | 0.77 | ADRB2 (0.44) | ADRB1ADRB2ADRB3 | |
| SCHEMBL5122655 | 0.76 | ADRB1 (0.66) | ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | claimed |
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2006-05-25 | — | — | US | claimed |
| EP-1525180-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-27 | — | — | EP | claimed |
| WO-2004016578-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-02-26 | — | — | WO | claimed |
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | ADRB2, ADRB1, ADRA2A | ADRB1 2/4885ADRB2 1/4885ADRB3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.